Full-Life Closes $37 Million Series A for Radiopharmaceutical Oncology Products
publication date: May 26, 2022
Shanghai Full-Life Technologies closed a $37 million Series A financing to develop its pipeline of radiopharmaceutical oncology products and radiotechnology production platform. Full-Life's discovery platform includes optimized single domain antibodies, peptides and linkers to radionuclides. It also pairs each development candidate with a theranostic nuclide to generate human PKPD data that guides patient selection before administering its therapeutic medicines. So far, Full-Life has disclosed three major targets, two of which are in IND development. The financing round was led by Sequoia China, together with Yunion Healthcare Ventures, Junson Capital, CD Capital and Kunlun Capital. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.